Nov 7 (Reuters) - 3M spin-off Solventum SOLV.N raised its annual profit forecast on Thursday, betting on strong sales of its wound care and surgical sterilization products.
The company now expects annual adjusted profit in the range of $6.50 to $6.65 per share, compared to its previous estimate of $6.30 to $6.50 per share.
Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities.
The company's net income fell to $122 million, or 70 cents per share, in the quarter ended Sept. 30, from $460 million, or $2.66 per share, a year earlier.
The company's profit fell by more than 70% in August on higher expenses — its first results as an independent company.
CEO Bryan Hanson said in August that the company is "currently assessing primary markets and growth drivers, and our intent is to finalize these decisions before the end of the year."
Total third-quarter net sales was $2.08 billion, a 0.4% increase from a year earlier.
More than half of Solventum's revenue comes from its MedSurg business, which provides wound dressings and surgical equipment. Third-quarter sales in the segment came in at $1.18 billion.
On an adjusted basis, Solventum earned a profit of $1.64 per share during the third quarter.
(Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber and Alan Barona)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。